We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » BMS Drops Opdivo Indication for Small Cell Lung Cancer
BMS Drops Opdivo Indication for Small Cell Lung Cancer
Bristol Myers Squibb has withdrawn the U.S. indication for its blockbuster drug Opdivo (nivolumab) for treatment of small cell lung cancer, following disappointing clinical trial results.